HC Wainwright Issues Pessimistic Forecast for CGTX Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Cognition Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.12) per share for the quarter, down from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS and FY2026 earnings at ($0.28) EPS.

Several other research firms also recently weighed in on CGTX. Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Chardan Capital reduced their price target on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $1.00 to $1.50 in a report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Cognition Therapeutics has a consensus rating of “Buy” and a consensus target price of $7.13.

Cognition Therapeutics Stock Performance

Shares of CGTX stock opened at $0.45 on Wednesday. Cognition Therapeutics has a 1 year low of $0.34 and a 1 year high of $2.95. The firm has a market capitalization of $18.73 million, a PE ratio of -0.46 and a beta of 1.03. The stock has a fifty day moving average of $0.56 and a two-hundred day moving average of $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same period last year, the company earned ($0.27) earnings per share.

Institutional Investors Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CGTX. BIOS Capital Management LP acquired a new position in shares of Cognition Therapeutics in the 4th quarter worth approximately $4,208,000. Sigma Planning Corp boosted its holdings in Cognition Therapeutics by 211.6% during the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after buying an additional 417,300 shares in the last quarter. Voss Capital LP acquired a new position in Cognition Therapeutics in the fourth quarter worth approximately $351,000. Geode Capital Management LLC increased its holdings in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after buying an additional 28,705 shares in the last quarter. Finally, Virtu Financial LLC lifted its position in shares of Cognition Therapeutics by 40.1% during the 4th quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after acquiring an additional 22,949 shares during the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.